Cystine has recently received regulatory approval in the UK for official anti-smoking use, available on prescription from 22 January.
A recent study by Argentine researchers revealed that a low-cost drug can more than double the chances of smokers quitting, marking the first innovative anti-smoking therapy in nearly two decades in many countries. Published in the scientific journal Dependence of December 31, the study highlights the safety and good tolerability of cytisinicline, also known as cystine.
Cytisinicline is an herbal medication and works by binding to nicotine receptors in the brain to reduce cravings for the substance and the severity of withdrawal symptoms. With a mechanism similar to varenicline (present in Pfizer’s Champix), cytisinicline was synthesized in 1964 in Bulgaria and, due to its herbal nature, has been used in Europe since the 1960s.
While it is not a new drug, rigorous clinical trials have recently been launched to demonstrate its potential to help smokers quit smoking. Cystine recently gained regulatory approval in the UK for official anti-smoking use, available on prescription from 22.
The study conducted by Omar de Santitoxicologist at the Hospital Nacional de Posadas, analyzed 12 clinical studies with almost six thousand volunteers, indicating that cytisinicline is an effective and convenient option for reducing smoking, especially in low- and middle-income countries.
Omar also told the scientific journal the following about the study: “Our study adds further evidence that cytisine is an effective and economical aid to smoking cessation. It could be very useful for reducing smoking in low- and middle-income countries, where cost-effective smoking cessation drugs are urgently needed. Worldwide, smoking is considered the leading cause of preventable death. Cytisine has the potential to be one of the great answers to this problem“.
Nancy Rigottiwho was previously director of the Tobacco Research and Treatment Center at Harvard University’s Massachusetts General Hospital, said in the post that “Smoking remains the leading preventable cause of death worldwide, but no new smoking cessation drugs have been approved by the FDA in nearly two decades. There is an urgent need for new drugs because current drugs do not help all smokers to quit and can have unacceptable side effects. If approved by regulators, cytisinicline could represent a valuable new option for treating tobacco dependenceThe pharmaceutical company plans to submit data to the US Food and Drug Administration (FDA) in 2024, seeking approval for use of the drug.
*Text under the supervision of Cleber Stevani.
Source: Terra
Ben Stock is a lifestyle journalist and author at Gossipify. He writes about topics such as health, wellness, travel, food and home decor. He provides practical advice and inspiration to improve well-being, keeps readers up to date with latest lifestyle news and trends, known for his engaging writing style, in-depth analysis and unique perspectives.
-qe3v951pr3g5.jpg "Caramel Mutt produces diabetic ‘guard’ tutor during the glycemic crisis")
